Paper42587147
Rb-driven transcription limits its tumour-suppressive effects in breast cancer.
Watt AC and 23 others. Nature, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Rb-driven transcription limits its tumour-suppressive effects in breast cancer. Papers, record 42587147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42587147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Retinoblastoma Protein | Major topic |
| Transcription, Genetic | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Genes, Tumor Suppressor | Major topic |
| Humans | |
| Female | |
| Animals | |
| Cyclin-Dependent Kinase 4 | |
| Cyclin-Dependent Kinase 6 | |
| Promoter Regions, Genetic | |
| Receptors, Estrogen | |
| Cell Line, Tumor | |
| Mice | |
| Phosphorylation | |
| Enhancer Elements, Genetic | |
| Cell Proliferation |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed |
Source NIH RePORTER
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9545246 | Rb binds c-Jun and activates transcription. | EMBO J | 1998 | https://conductscience.org/library/papers/9545246 | PubMed |
| 2 | 1321348 | Retinoblastoma protein switches the E2F site from positive to negative element. | Nature | 1992 | https://conductscience.org/library/papers/1321348 | PubMed |
| 3 | 18650841 | Cellular mechanisms of tumour suppression by the retinoblastoma gene. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/18650841 | PubMed |
| 4 | 29483214 | Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. | Mol Cancer Ther | 2018 | https://conductscience.org/library/papers/29483214 | PubMed |
| 5 | 34433817 | Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. | Nat Commun | 2021 | https://conductscience.org/library/papers/34433817 | PubMed |
| 6 | 11484059 | Rb targets histone H3 methylation and HP1 to promoters. | Nature | 2001 | https://conductscience.org/library/papers/11484059 | PubMed |
| 7 | 37648594 | Patterns in the tapestry of chromatin-bound RB. | Trends Cell Biol | 2024 | https://conductscience.org/library/papers/37648594 | PubMed |
| 8 | 20513432 | Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. | Mol Cell | 2010 | https://conductscience.org/library/papers/20513432 | PubMed |
| 9 | 24263090 | Target analysis by integration of transcriptome and ChIP-seq data with BETA. | Nat Protoc | 2013 | https://conductscience.org/library/papers/24263090 | PubMed |
| 10 | 25501126 | CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25501126 | PubMed |
| 11 | 34723319 | The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. | Nucleic Acids Res | 2022 | https://conductscience.org/library/papers/34723319 | PubMed |
| 12 | 35085776 | SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. | Genomics Proteomics Bioinformatics | 2022 | https://conductscience.org/library/papers/35085776 | PubMed |
| 13 | 1531329 | The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. | Genes Dev | 1992 | https://conductscience.org/library/papers/1531329 | PubMed |
| 14 | 42587147 | Rb-driven transcription limits its tumour-suppressive effects in breast cancer. | Nature | 2026 | https://conductscience.org/library/papers/42587147 | PubMed |
| 15 | 31353221 | Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. | Cell | 2019 | https://conductscience.org/library/papers/31353221 | PubMed |
| 16 | 30101006 | An end to end workflow for differential gene expression using Affymetrix microarrays. | F1000Res | 2016 | https://conductscience.org/library/papers/30101006 | PubMed |
| 17 | 34544752 | INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34544752 | PubMed |
| 18 | 26977878 | Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. | Cancer Cell | 2016 | https://conductscience.org/library/papers/26977878 | PubMed |
| 19 | 29073143 | BBMerge - Accurate paired shotgun read merging via overlap. | PLoS One | 2017 | https://conductscience.org/library/papers/29073143 | PubMed |
| 20 | 24227677 | featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. | Bioinformatics | 2014 | https://conductscience.org/library/papers/24227677 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42706313 | The secret life of a cell-cycle gatekeeper of breast cancer. | Nature | 2026 | https://conductscience.org/library/papers/42706313 | PubMed |
| 42587147 | Rb-driven transcription limits its tumour-suppressive effects in breast cancer. | Nature | 2026 | https://conductscience.org/library/papers/42587147 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| KDM5A | 5927 | PubTator's text mining | https://conductscience.org/library/genes/5927 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42587147
GET https://conductscience.org/api/papers/v1/42587147/authors?page=2